Background Bevacizumab is approved for the treatment of patients with progressive glioblastoma
on the basis of uncontrolled data. Data from a phase 2 trial suggested that the addition …

Purpose Approximately 50% of glioblastomas (GBMs) are characterized by overexpression
of the epidermal growth factor receptor (EGFR) and EGFR gene amplification. In …

Background Outcome of low-grade glioma (WHO grade II) is highly variable, reflecting
molecular heterogeneity of the disease. We compared two different, single-modality treatment …

Background Patients with recurrent or metastatic squamous-cell carcinoma of the head and
neck (HNSCC) progressing after first-line platinum regimens have a poor prognosis and few …

Background Targeting the programmed cell death protein 1 (PD-1)/programmed cell death
ligand 1 (PD-L1) axis has demonstrated clinical benefit in recurrent/metastatic head and neck …

Background The CATNON trial investigated the addition of concurrent, adjuvant, and both
current and adjuvant temozolomide to radiotherapy in adults with newly diagnosed 1p/19q non…

Background The role of temozolomide chemotherapy in newly diagnosed 1p/19q non-co-deleted
anaplastic gliomas, which are associated with lower sensitivity to chemotherapy and …

Background Patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M
HNSCC) progressing on platinum-based chemotherapy have poor prognoses and limited …

Background Depatuxizumab mafodotin (Depatux-M) is a tumor-specific antibody–drug conjugate
consisting of an antibody (ABT-806) directed against activated epidermal growth factor …

Immunogenic cell death (ICD) refers to an immunologically distinct process of regulated cell
death that activates, rather than suppresses, innate and adaptive immune responses. Such …